Reinventing
Biopharma

Roivant is focused on rapidly developing innovative medicines through a novel form of industrial organization in R&D.

About Roivant

Roivant aims to improve health by rapidly delivering innovative medicines and technologies to patients. We do this by building Vants – nimble, entrepreneurial biotech and healthcare technology companies with a unique approach to sourcing talent, aligning incentives, and deploying technology.

We have built 15 Vants to date and have raised over $3 billion to pursue our mission. The therapies in development across our family of companies target a wide range of diseases including uterine fibroids, endometriosis, prostate cancer, Parkinson’s disease, diabetes, sickle cell disease, and multiple rare and fatal pediatric conditions.

In addition to our biopharmaceutical subsidiaries, we also build technology-focused Vants focused on improving the process of developing and commercializing medicines.

 

Founder and CEO Vivek Ramaswamy at 37th Annual J.P. Morgan Healthcare Conference

Vivek Ramaswamy Presents at Roivant Pipeline Day 2018

OUR VANTS

Myovant

Dedicated to women’s health and prostate cancer.

OUR VANTS

Enzyvant

Developing transformative therapies for patients with rare diseases.

OUR VANTS

Axovant

Finding new solutions in neurology.

OUR VANTS

Metavant

Looking beyond the current options for cardiometabolic disorders.

OUR VANTS

Urovant

Improving quality of life through advancements in urology.

OUR VANTS

Dermavant

Leading innovation in medical dermatology.

OUR VANTS

Sinovant

Bringing medical innovation to China.

OUR VANTS

Genevant

Delivering results through RNA therapeutics.

OUR VANTS

Altavant

Elevating patient-centric drug development.

OUR VANTS

Arbutus

Working towards a cure for hepatitis B.

OUR VANTS

Respivant

Serving patients suffering from respiratory diseases.

OUR VANTS

Immunovant

Breaking barriers in immunology to restore patient health.

OUR VANTS

Aruvant

Developing gene therapies for hematological conditions.

OUR VANTS

Alyvant

Using data to connect patients to therapies.

OUR VANTS

Datavant

Organizing the world's healthcare data.

OUR WORK

Pipeline

We have a diverse pipeline of over 35 investigational drugs in 14 therapeutic areas across our family of companies.

COMPANY
COMPOUND
INDICATION
PHASE
Company Compound Indication PRECLIN Phase 1 Phase 2 Phase 3
ENZYVANT RVT-802

Complete DiGeorge Anomaly

3

UROVANT VIBEGRON

Overactive Bladder

3

Overactive Bladder in Men with BPH

3

MYOVANT RELUGOLIX

Uterine Fibroids

3

Endometriosis

3

Prostate Cancer

3

SINOVANT DERAZANTINIB

Intrahepatic Cholangiocarcinoma

3

LEFAMULIN

Community-Acquired Bacterial Pneumonia

3

BB3

Delayed Graft Function

3

Acute Kidney Injury

2

ARUVANT ARU-1801

Sickle Cell Disease and β-Thalassemia

2

AXOVANT AXO-LENTI-PD

Parkinson's Disease

2

DERMAVANT TAPINAROF

Psoriasis, Atopic Dermatitis

2

IMMUNOVANT IMVT-1401

Autoimmune Disorders

2

METAVANT RVT-1501

Diabetes

2

RVT-1502

Diabetes

2

MYOVANT MVT-602

Female Infertility

2

RESPIVANT RVT-1601

IPF with Chronic Cough

2

SINOVANT NARONAPRIDE

IBS-C

2

AXOVANT AXO-AAV-GM2

Tay-Sachs/Sandhoff Disease

2

AXO-AAV-GM1

GM1 Gangliosidosis

2

UROVANT VIBEGRON

IBS-Associated Pain

1

ALTAVANT RODATRISTAT ETHYL

Pulmonary Arterial Hypertension

1

DERMAVANT DMVT-502

Atopic Dermatitis, Vitiligo

1

UROVANT URO-902

Overactive Bladder

1

Arbutus AB-506

Hepatitis B

1

ENZYVANT RVT-801

Farber Disease

Preclin

AXOVANT AXO-AAV-OPMD

Oculopharyngeal Muscular Dystrophy

Preclin

DERMAVANT DMVT-504

Primary Focal Hyperhidrosis

Preclin

DMVT-501

Atopic Dermatitis

Preclin

DMVT-503

Acne Vulgaris

Preclin

GENEVANT 5 mRNA Programs

Rare Diseases

Preclin

Additional pan-RNA Programs

Genetic Disorders

Preclin

Arbutus AB-452

Hepatitis B

Preclin

AB-729

Hepatitis B

Preclin

OUR PEOPLE

Leadership

Our leadership team includes industry veterans as well as exceptional leaders from outside of pharma.

The management teams of our subsidiary companies feature some of the most accomplished executives in the biopharmaceutical industry.

Our directors have deep experience in pharmaceutical business development, academic research, public policy, and life sciences investing.

Members of our Public Stakeholder Advisory Group (PSAG) provide ongoing advice on how Roivant can play a role in improving the healthcare system.

WHO WE WORK WITH

Partners

We build our Vants through partnerships with companies and academic institutions that share our commitment to developing new medicines for patients and delivering innovation in healthcare. Select partners are listed below.

STAY INFORMED

News

GET IN TOUCH

Contact Us

Basel, Switzerland
Roivant Sciences GmbH
Viaduktstrasse 8
4051 Basel
Switzerland
New York, NY
Roivant Sciences, Inc.
320 West 37th Street
6th Floor
New York, NY 10018
United States
Durham, NC
Roivant Sciences, Inc.
324 Blackwell Street
Bay 12, Suite 1220
Durham, NC 27701
United States
San Francisco, CA
Myovant Sciences, Inc.
2000 Sierra Point Parkway
9th Floor
Brisbane, CA 94005
United States
Cambridge, MA
Enzyvant
55 Cambridge Parkway
Suite 900E
Cambridge, MA 02142
United States
Irvine, CA
Urovant Sciences, Inc.
5151 California Avenue
Suite 250
Irvine, CA 92617
United States
Phoenix, AZ
Dermavant Sciences, Inc.
2398 East Camelback Road
Suite 1060
Phoenix, AZ 85016
United States
Warminster, PA
Arbutus Biopharma Corporation
701 Veterans Circle
Warminster, PA 18974
United States
San Diego, CA
Respivant Sciences, Inc.
11455 El Camino Real
Suite 460
San Diego, CA 92130
United States
Vancouver, BC
Genevant Sciences Corporation
8900 Glenlyon Parkway
Burnaby, British Columbia V5J 5J8
Canada
Beijing, China
Sinovant Sciences
77 Jianguo Road
Room 2601-2602A
Chaoyang District
Beijing 100025
China
Shanghai, China
Sinovant Sciences
1717 Nanjing West Road
Room 25, 42nd Floor
Jingan District
Shanhai 200040
China